Molecular Oncology
Volume 4, Issue 4 , Pages 309-322 , August 2010

Cytogenomics of cancers: From chromosome to sequence

  • Alain Bernheim

      Affiliations

    • Corresponding Author InformationTel.: +33 (0) 1 42 11 47 79; fax: +33 (0) 1 42 11 52 60.

Received 20 May 2010 ,Accepted 2 June 2010.

References 

  1. Albertson D, Collins C, McCormick F, Gray J. Chromosome aberrations in solid tumors. Nat. Genet. 2003;34:369–376
  2. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin. Cancer Res. 2009;15:441–451
  3. Argani P, Lui MY, Couturier J, Bouvier R, Fournet JC, Ladanyi M. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene. 2003;22:5374–5378
  4. Balmain A. Cancer genetics: from Boveri and Mendel to microarrays. Nat. Rev. Cancer. 2001;1:77–82
  5. Berger R, Bernheim A, Gluckman E, Gisselbrecht C. In vitro effect of cyclophosphamide metabolites on chromosomes of Fanconi anaemia patients. Br. J. Haematol. 1980;45:565–568
  6. Bernheim A, Berger R, Lenoir G. Cytogenetic studies on African Burkitt’s lymphoma cell lines: t(8;14), t(2;8) and t(8;22) translocations. Cancer. Genet. Cytogenet. 1981;3:307–315
  7. Bernheim A, Berger R, Preud’homme JL, Labaume S, Bussel A, Barot-Ciorbaru R. Philadelphia chromosome positive blood B lymphocytes in chronic myelocytic leukemia. Leuk. Res. 1981;5:331–339
  8. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across. Nature. 2010;463:899–905
  9. Bignell GR, Santarius T, Pole JC, Butler AP, Perry J, Pleasance E, et al. Architectures of somatic genomic rearrangement in sequence-level resolution. Genome Res. 2007;17:1296–1303
  10. Boveri T. Zur Frage der Entstehung Maligner Tumoren. Jena: Gustav Fisher; 1914;
  11. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100–104
  12. Calin GA, Croce CM. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood. 2009;114:4761–4770
  13. Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am. J. Surg. Pathol. 2008;32:656–670
  14. Castaigne S, Berger R, Jolly V, Daniel MT, Bernheim A, Marty M, et al. Promyelocytic blast crisis of chronic myelocytic leukemia with both t(9;22) and t(15;17) in M3 cells. Cancer. 1984;54:2409–2413
  15. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature. 2008;452:553–563
  16. Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 2003;348:1201–1204
  17. Couturier J, Vincent-Salomon A, Mathieu MC, Valent A, Bernheim A. Diagnosis of HER2 gene amplification in breast carcinoma. Pathol. Biol. (Paris). 2008;
  18. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009;10:704–714
  19. Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 2010;16:291–303
  20. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162–165
  21. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al The Ewing family of tumors – a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N. Engl. J. Med. 1994;331:294–299
  22. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808–4817
  23. Druker BJ. Perspectives on the development of imatinib and the future of cancer research. Nat. Med. 2009;15:1149–1152
  24. Duffaud F, Le Cesne A. Imatinib in the treatment of solid tumours. Target. Oncol. 2009;4:45–56
  25. Fagin JA. Perspective: lessons learned from molecular genetic studies of thyroid cancer – insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology. 2002;143:2025–2028
  26. Frohling S, Dohner H. Chromosomal abnormalities in cancer. N. Engl. J. Med. 2008;359:722–734
  27. Gisselsson D. Chromosomal instability in cancer: causes and consequences. Atlas Genet. Cytogenet. Oncol. Haematol. 2001;
  28. Gluckman E, Devergie A, Schaison G, Bussel A, Berger R, Sohier J, et al. Bone marrow transplantation in Fanconi anaemia. Br. J. Haematol. 1980;45:557–564
  29. Guillaud-Bataille M, Brison O, Danglot G, Lavialle C, Raynal B, Lazar V, et al. Two populations of double minute chromosomes harbor distinct amplicons, the MYC locus at 8q24.2 and a 0.43-Mb region at 14q24.1, in the SW613-S human carcinoma cell line. Cytogenet. Genome Res. 2009;124:1–11
  30. Hanna W. Testing for HER2 status. Oncology. 2001;61:22–30
  31. Huret J. MLL (myeloid/lymphoid or mixed lineage leukemia). Atlas Genet. Cytogenet. Oncol. Haematol. 2009;URL: http://AtlasGeneticsOncology.org/Genes/MLL.html
  32. Huret JL. Atlas Genet. Cytogenet. Oncol. Haematol. 2010;
  33. Huret JL, Dessen P, Bernheim A. Atlas Genet. Cytogenet. Oncol. Haematol. 2001;29:303–304updated. Nucl. Acids Res.
  34. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J. Clin. Oncol. 2009;27:1026–1033
  35. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992;258:818–821
  36. Lenoir G, Preud’homme JL, Bernheim A, Berger R. Correlation between variant translocation and the expression of immunoglobulin light chains in Burkitt-type lymphomas and leukemias. C. R. Seances Acad. Sci. III. 1981;293:427–429
  37. Lenoir GM, Preud’homme JL, Bernheim A, Berger R. Correlation between immunoglobulin light chain expression and variant translocation in Burkitt’s lymphoma. Nature. 1982;298:474–476
  38. Lynch A, Morton C. Uterus: leiomyoma. Atlas Genet. Cytogenet. Oncol. Haematol. 2007;
  39. Mandahl N. Soft tissue tumors: lipoma/benign lipomatous tumors. Atlas Genet. Cytogenet. Oncol. Haematol. 2000;
  40. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science. 2009;326:1230
  41. Mardis ER. New strategies and emerging technologies for massively parallel sequencing: applications in medical research. Genome Med. 2009;1:40
  42. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 2009;361:1058–1066
  43. Mitelman F, Johansson B, Mertens F. Database of Chromosome Aberrations in Cancer. 2003;http://cgap.nci.nih.gov/Chromosomes/Mitelman
  44. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer. 2007;7:233–245
  45. Moldovan GL, D’Andrea AD. How the fanconi anemia pathway guards the genome. Annu. Rev. Genet. 2009;43:223–249
  46. NCI , NCBI . NCI and NCBI’s SKY/M-FISH and CGH Database. 2001;http://www.ncbi.nlm.nih.gov/sky/skyweb.cgi
  47. Nikiforov YE. Radiation-induced thyroid cancer: what we have learned from chernobyl. Endocr. Pathol. 2006;17:307–317
  48. Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19:1351–1361
  49. Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science. 2000;290:138–141
  50. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J. Natl. Cancer Inst. 1960;25:85–109
  51. O’Sullivan RJ, Karlseder J. Telomeres: protecting chromosomes against genome instability. Nat. Rev. Mol. Cell. Biol. 2010;11:171–181
  52. Pierotti M. Chromosomal rearrangements in thyroid carcinomas: a recombination or death dilemma. Cancer Lett. 2001;166:1–7
  53. Pinkel D, Albertson DG. Array comparative genomic hybridization and its applications in cancer. Nat Genet. 2005;37(Suppl):S11–S17
  54. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463:191–196
  55. Qian Z, Joslin JM, Tennant TR, Reshmi SC, Young DJ, Stoddart A, et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem. Biol. Interact. 2009;
  56. Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett. 2007;254:1–10
  57. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293
  58. Rowley JD. The critical role of chromosome translocations in human leukemias. Annu. Rev. Genet. 1998;32:495–519
  59. Sandberg A. Cytogenetics and molecular genetics of bone and soft-tissue tumors. Am. J. Med. Genet. 2002;115:189–193
  60. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nat. Rev. Cancer. 2010;10:59–64
  61. Schvartzman JM, Sotillo R, Benezra R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat. Rev. Cancer. 2010;10:102–115
  62. Schwab M. MYCN in neuronal tumours. Cancer Lett. 2004;204:179–187
  63. Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J. Clin. Invest. 2007;117:2067–2074
  64. Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, et al. Lung adenocarcinoma with EGFR amplification has molecular features in never-smokers. Cancer Res. 2009;69:8341–8348
  65. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion cancer. Nature. 2007;448:561–566
  66. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. fourth ed.. Geneva: WHO Press; 2008;
  67. Thompson CB. Attacking cancer at its root. Cell. 2009;138:1051–1054
  68. Toledo LM, Lydon NB, Elbaum D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 1999;6:775–805
  69. Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94:935–943
  70. Toujani S, Dessen P, Ithzar N, Danglot GL, Richon C, Vassetzky Y, et al. High resolution genome-wide analysis of chromosomal alterations in Burkitt’s lymphoma. PLoS ONE. 2009;4:e7089
  71. Tronko MD, Howe GR, Bogdanova TI, Bouville AC, Epstein OV, Brill AB, et al. A cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: thyroid cancer in Ukraine detected during first screening. J. Natl. Cancer Inst. 2006;98:897–903
  72. Valent A, Venuat AM, Danglot G, Da Silva J, Duarte N, Bernheim A, et al. Stromal cells and human malignant neuroblasts derived from bone marrow metastasis may share common karyotypic abnormalities: the case of the IGR-N-91 cell line. Med. Pediatr. Oncol. 2001;36:100–103
  73. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505–2515
  74. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N. Engl. J. Med. 1989;320:1047–1054

PII: S1574-7891(10)00049-9

doi: 10.1016/j.molonc.2010.06.003

Molecular Oncology
Volume 4, Issue 4 , Pages 309-322 , August 2010

Article Tools

* Image Usage & Resolution